PTO/SB/08a (05-07)
Approved for use through 09/30/2007 OMB 0651-0031
U S Patent and Trademark Office, U S DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

( Not for submission under 37 CFR 1.99)

| | |
|---|---|
| Application Number | 10577167 |
| Filing Date | 2007-08-05 |
| First Named Inventor | David M. Briscoe |
| Art Unit | 1644 |
| Examiner Name | |
| Attorney Docket Number | 701039-053522 |

**U.S.PATENTS** Remove

| Examiner Initial* | Cite No | Patent Number | Kind Code[1] | Issue Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|---|
| | 1 | | | | | |

If you wish to add additional U.S. Patent citation information please click the Add button. Add

**U.S.PATENT APPLICATION PUBLICATIONS** Remove

| Examiner Initial* | Cite No | Publication Number | Kind Code[1] | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear |
|---|---|---|---|---|---|---|
| | 1 | | | | | |

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

**FOREIGN PATENT DOCUMENTS** Remove

| Examiner Initial* | Cite No | Foreign Document Number[3] | Country Code[2] i | Kind Code[4] | Publication Date | Name of Patentee or Applicant of cited Document | Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear | T[5] |
|---|---|---|---|---|---|---|---|---|
| | 1 | | | | | | | ☐ |

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

**NON-PATENT LITERATURE DOCUMENTS** Remove

| Examiner Initials* | Cite No | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published. | T[5] |
|---|---|---|---|

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99) | | |
|---|---|---|
| | Application Number | 10577167 |
| | Filing Date | 2007-08-05 |
| | First Named Inventor | David M. Briscoe |
| | Art Unit | 1644 |
| | Examiner Name | |
| | Attorney Docket Number | 701039-053522 |

| | | | |
|---|---|---|---|
| | 1 | SIDKY, Y.A. and AUERBACH, R. 1975. Lymphocyte-induced angiogenesis: a quantitative and sensitive assay of the graft-vs.-host reaction. J Exp Med 141:1084-1100. | ☐ |
| | 2 | AUERBACH, R. and SIDKY, Y.A. 1979. Nature of the stimulus leading to lymphocyte-induced angiogenesis. J Immunol 123:751-754. | ☐ |
| | 3 | Chapter 3, Inflammation and repair. In: Cotran RS, Kumar V, Robbins SL, editors. Pathologic Basis of Disease. WB Saunders, Philidelphia. 51-92, 1994. | ☐ |
| | 4 | MOULTON, K.S., et al. 1999. Angiogenesis in the huPBL-SCID model of human transplant rejection. Transplantation 67:1626-1631. | ☐ |
| | 5 | LEUNG, D.W., et al. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309. | ☐ |
| | 6 | FOLKMAN, J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1. 27-31. | ☐ |
| | 7 | FERRARA, N. and DAVIS-SMYTH, T. 1997. The biology of vascular endothelial growth factor. Endocr Rev 18:4-25. | ☐ |
| | 8 | GERBER, H.P., et al. 1998. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 273:13313-13316. | ☐ |
| | 9 | MELDER, R.J., et al. 1996. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 2:992-997. | ☐ |
| | 10 | KIM, I., et al. 2001. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 276:7614-7620. | ☐ |
| | 11 | BARLEON, B., et al. 1996. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 87:3336-3343. | ☐ |

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99) | | |
|---|---|---|
| | Application Number | 10577167 |
| | Filing Date | 2007-08-05 |
| | First Named Inventor | David M. Briscoe |
| | Art Unit | 1644 |
| | Examiner Name | |
| | Attorney Docket Number | 701039-053522 |

| | | | |
|---|---|---|---|
| | 12 | MELTER, M., et al. 2000. Ligation of CD40 induces the expression of vascular endothelial growth factor by endothelial cells and monocytes and promotes angiogenesis in vivo. Blood 96:3801-3808. | ☐ |
| | 13 | FREEMAN, M.R., et al. 1995. Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. Cancer Res 55:4140-4145. | ☐ |
| | 14 | SOKER, S., et al. 1996. Characterization of novel vascular endothelial growth factor (VEGF) receptors on tumor cells that bind VEGF165 via its exon 7-encoded domain. J Biol Chem 271:5761-5767. | ☐ |
| | 15 | CLAUSS, M., et al. 1996. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271:17629-17634. | ☐ |
| | 16 | SHWEIKI, D., et al. 1992. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845. | ☐ |
| | 17 | SATO, K., et al. 1995. Stimulation by thyroid-stimulating hormone and Grave's immunoglobulin G of vascular endothelial growth factor mRNA expression in human thyroid follicles in vitro and flt mRNA expression in the rat thyroid in vivo. J Clin Invest 96:1295-1302. | ☐ |
| | 18 | SHWEIKI, D., et al. 1995. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implications for tumor angiogenesis. Proc Natl Acad Sci U S A 92:768-772. | ☐ |
| | 19 | WILLIAMS, B., et al. 1995. Angiotensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells. Hypertension 25:913-917. | ☐ |
| | 20 | WILLIAMS, B., et al. 1995. Serum and platelet-derived growth factor-induced expression of vascular permeability factor mRNA by human vascular smooth muscle cells in vitro. Clin Sci 88:141-147. | ☐ |
| | 21 | REINDERS, M. E., et al. Proangiogenic function of CD40 ligand-CD40 interactions. J Immunol 171(3), 1534-41. 2003. | ☐ |
| | 22 | REINDERS, M. E. J., et al. Expression patterns of vascular endothelial growth factor in human cardiac allografts: association with rejection. Transplantation 76(1), 224-30. 2003. | ☐ |

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99) | | |
|---|---|---|
| | Application Number | 10577167 |
| | Filing Date | 2007-08-05 |
| | First Named Inventor | David M. Briscoe |
| | Art Unit | 1644 |
| | Examiner Name | |
| | Attorney Docket Number | 701039-053522 |

| | | | |
|---|---|---|---|
| | 23 | SHAHBAZI, M., et al. 2002. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 13:260-264. | ☐ |
| | 24 | PILMORE, H.L., et al. 1999. Vascular endothelial growth factor expression in human chronic renal allograft rejection. Transplantation 67:929-933. | ☐ |
| | 25 | TORRY, R.J., et al. 1995. Vascular endothelial growth factor expression in transplanted human hearts. Transplantation 60:1451-1457. | ☐ |
| | 26 | KIM, K.J., et al. 1993. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841-4. | ☐ |
| | 27 | PRESTA, L. G., et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57(20), 4593-9, 1997. | ☐ |
| | 28 | KHAN, I.A., et al. 2000. IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 12:483-494. | ☐ |
| | 29 | O'REILLY, M.S., et al. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-85. | ☐ |
| | 30 | BOEHM, T., et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-7, 1997. | ☐ |
| | 31 | BERGERS, G., et al. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-12, 1999. | ☐ |
| | 32 | TILTON, R.G., et al. 1997. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor J Clin Invest 99:2192-2202. | ☐ |
| | 33 | BASU, S., et al. 2001. The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/ vascular endothelial growth factor. Nat Med 7:569-574. | ☐ |

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99) | | |
|---|---|---|
| | Application Number | 10577167 |
| | Filing Date | 2007-08-05 |
| | First Named Inventor | David M. Briscoe |
| | Art Unit | 1644 |
| | Examiner Name | |
| | Attorney Docket Number | 701039-053522 |

| | | | |
|---|---|---|---|
| | 34 | WALTER, D.H., et al. et al. 1996. The in vivo bioactivity of vascular endothelial growth factor/vascular permeability factor is independent of N-linked glycosylation. Lab Invest 74:546-556. | ☐ |
| | 35 | DUFOUR, J.H., et al. 2002. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168:3195-3204. | ☐ |
| | 36 | BRISCOE, D.M., et al. 1999. The allogeneic response to cultured human skin equivalent in the hu-PBL-SCID mouse model of skin rejecton. Transplantation 67:1590-1599. | ☐ |
| | 37 | CORRY, R.J., et al. 1973. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 16:343-350. | ☐ |
| | 38 | LU, J., et al. 2000. Vascular endothelial growth factor expression and regulation of murine collagen-induced arthritis. J Immunol 164:5922-5927. | ☐ |
| | 39 | HANCOCK, W.W., et al. 2001. Donor-derived IP-10 initiates development of acute allograft rejection. J Exp Med 193:975-980. | ☐ |
| | 40 | YAMADA, A., et al. 2001. CD28-independent costimulation of T cells in alloimmune responses. J Immunol 167:140-146. | ☐ |
| | 41 | GIMBRONE, M.A. 1976. Culture of vascular endothelium. Prog Hemost Thromb 3:1-28. | ☐ |
| | 42 | MARELLI-BERG, F.M., 2000. Isolation of endothelial cells from murine tissue. J Immunol Methods 244:205-215. | ☐ |
| | 43 | DENTON, M.D., et al. 1999. Endothelial cells modify the costimulatory capacity of transmigrating leukocytes and promote CD28-mediated CD4+ T cell alloactivation. J Exp Med 190:555-566. | ☐ |
| | 44 | MURRAY, A.G., et al. 1994. Human T-cell-mediated destruction of allogeneic dermal microvessels in a severe combined immunodeficient mouse. Proc Natl Acad Sci U S A 91:9146-9150. | ☐ |

| INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99) | | |
|---|---|---|
| | Application Number | 10577167 |
| | Filing Date | 2007-08-05 |
| | First Named Inventor | David M. Briscoe |
| | Art Unit | 1644 |
| | Examiner Name | |
| | Attorney Docket Number | 701039-053522 |

| | | | |
|---|---|---|---|
| | 45 | LUSTER, A D., et al 1987. Interferon-inducible gene maps to a chromosomal band associated with a (4,11) translocation in acute leukemia cells. Proc Natl Acad Sci U S A 84:2868-2871. | ☐ |

If you wish to add additional non-patent literature document citation information please click the Add button Add

**EXAMINER SIGNATURE**

| Examiner Signature | | Date Considered | |
|---|---|---|---|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.